Document is current
Any future updates will be listed below
-
Authors
De Alcubierre, Dario https://orcid.org/0000-0001-5242-1761
Feola, Tiziana https://orcid.org/0000-0003-1066-0064
Cozzolino, Alessia https://orcid.org/0000-0001-8614-5873
Pofi, Riccardo https://orcid.org/0000-0001-7808-5735
Galea, Nicola https://orcid.org/0000-0003-4708-5120
Catalano, Carlo https://orcid.org/0000-0003-4208-9691
Auriemma, Renata Simona
Pirchio, Rosa
Pivonello, Rosario https://orcid.org/0000-0002-9632-1348
Isidori, Andrea M. https://orcid.org/0000-0002-9037-5417
Giannetta, Elisa https://orcid.org/0000-0003-3614-6151
-
Funding
Funding for this research was provided by:
Università degli Studi di Roma La Sapienza
- License Information
-
More Information
Article History
Accepted: 11 May 2024
First Online: 7 June 2024
Declarations
:
: This study protocol was reviewed and approved by the Ethical Committee of Policlinico Umberto I, approval number 4244.
: All patients provided written informed consent to participate after receiving a full explanation of the purpose and nature of all procedures used in the study.
: RPi has received research support to Università Federico II di Napoli as a principal investigator for clinical trials from Novartis Pharma, Recordati, Strongbridge Biopharma, Corcept Therapeutics, HRA Pharma, Shire, Takeda, Neurocrine Biosciences, Camurus AB, and Pfizer, has received research support to Università Federico II di Napoli from Pfizer, Ipsen, Novartis Pharma, Strongbridge Biopharma, Merk Serono, and Ibsa, and received occasional consulting honoraria from Novartis Pharma, Recordati, Strongbridge Biopharma, HRA Pharma, Crinetics Pharmaceuticals, Corcept Therapeutics, Pfizer, and Bresmed Health Solutions. AMI has served as a consultant for Novartis, Takeda, Recordati, and Sandoz companies, has received unconditional research grants from Shire, IPSEN, and Pfizer. All the other authors have nothing to disclose.
